Prothena
PRTA | NASDAQ
$7.97
-$0.19 (-2.33%)
At close: Nov 16, 2026, 4:00 PM ET
$7.97
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Prothena Company Profile
Company profile explainedCompany Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Key Executives
| Name | Position |
|---|---|
| Gene G. Kinney | President, Chief Executive Officer & Director |
| Brandon S. Smith | Chief Operating Officer |
| Tran Nguyen | Chief Financial Officer |
| Annie Evans Kingston | Chief Strategy Officer |
| Chad Swanson | Chief Development Officer |
| Karin L. Walker | Chief Accounting Officer & Controller |
| Mark C. Johnson | Vice President of Investor Relations |
| Michael J. Isaacs | General Counsel & Corporate Secretary |
| Phillip Dolan | Sr. Director & Head of Exploratory Research |
| Wagner Zago | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 4 | Filing |
| Oct 26, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 09, 2026 | 4 | Filing |
| Oct 06, 2026 | 4 | Filing |
| Oct 02, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
Prothena
| Country | Ireland |
| IPO Date | Dec 20, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Gene G. Kinney |
Contact Details
77 Sir John Rogerson’s Quay Dublin,
DU D02 VK60 Ireland
Stock Details
| Ticker Symbol | PRTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001559053 |
| CUSIP Number | n/a |
| ISIN Number | IE00B91XRN20 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PRTA